Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, April 19 '25)

Image
By G.M.

 


    Am J Respir Crit Care Med

  1. BALTE PP, Kim JS, Sun Y, Allen N, et al
    Associations of Pre-Pandemic Lung Function and Structure with COVID-19 Outcomes: The C4R Study.
    Am J Respir Crit Care Med. 2025 Apr 16. doi: 10.1164/rccm.202408-1656.
    PubMed         Abstract available


    Antiviral Res

  2. KELLY JA, Aida-Ficken V, McMullan LK, Chatterjee P, et al
    Mechanisms of action of repurposed Ebola virus antivirals - the roles of phospholipidosis and cholesterol homeostasis.
    Antiviral Res. 2025 Apr 15:106167. doi: 10.1016/j.antiviral.2025.106167.
    PubMed         Abstract available


    Clin Infect Dis

  3. MESSCHENDORP AL, Zaeck LM, Bouwmans P, van den Broek DAJ, et al
    Replacing Mycophenolate Mofetil by Everolimus in Kidney Transplant Recipients to Increase Vaccine Immunogenicity: Results of a Randomized Controlled Trial.
    Clin Infect Dis. 2025 Apr 15:ciaf107. doi: 10.1093.
    PubMed         Abstract available


    Eur J Radiol

  4. FERRETTI AE, Mercaldo ND, Li X, Rehani MM, et al
    Assessing trends in patients undergoing recurrent CT examinations and cumulative doses.
    Eur J Radiol. 2025;187:112099.
    PubMed         Abstract available


    Int J Infect Dis

  5. CHEN W, Du M, Deng J, Liu M, et al
    Global, regional, and national trends of measles burden and its vaccination coverage among children under five years old: an updated systematic analysis from the Global Burden of Disease study 2021.
    Int J Infect Dis. 2025 Apr 15:107908. doi: 10.1016/j.ijid.2025.107908.
    PubMed         Abstract available


    Intensive Care Med

  6. BOERS LS, van Someren Greve F, van Hattem JM, de Brabander J, et al
    Correction: Pulmonary herpes simplex virus and cytomegalovirus in patients with acute respiratory distress syndrome related to COVID-19.
    Intensive Care Med. 2025 Apr 14. doi: 10.1007/s00134-025-07854.
    PubMed        


    J Med Virol

  7. CHUANG CH, Wang YH, Yeh LT, Yeh CB, et al
    Long-Term Stroke and Mortality Risk Reduction Associated With Acute-Phase Paxlovid Use in Mild-to-Moderate COVID-19.
    J Med Virol. 2025;97:e70351.
    PubMed         Abstract available

  8. SULAIMAN X, Han Y, Liu S, Li K, et al
    Enrichment of G-to-U Substitution in SARS-CoV-2 Functional Regions and Its Compensation via Concurrent Mutations.
    J Med Virol. 2025;97:e70353.
    PubMed         Abstract available


    J Virol

  9. KAWAKITA T, Sekiya T, Kameda Y, Nomura N, et al
    ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4(+) and CD8(+) T-cell responses and neutralizing antibody induction.
    J Virol. 2025 Apr 15:e0229024. doi: 10.1128/jvi.02290.
    PubMed         Abstract available

  10. KRAMMER F, Hermann E, Rasmussen AL
    Highly pathogenic avian influenza H5N1: history, current situation, and outlook.
    J Virol. 2025 Mar 27:e0220924. doi: 10.1128/jvi.02209.
    PubMed         Abstract available

  11. XIE H, Xiong T, Guan J, Han Y, et al
    Induction of mitochondrial damage via the CREB3L1/miR-34c/COX1 axis by porcine epidemic diarrhea virus infection facilitates pathogenicity.
    J Virol. 2025;99:e0059124.
    PubMed         Abstract available

  12. LI Y, Yang S, Qian J, Liu S, et al
    Molecular characteristics of the immune escape of coronavirus PEDV under the pressure of vaccine immunity.
    J Virol. 2025 Apr 16:e0219324. doi: 10.1128/jvi.02193.
    PubMed         Abstract available

  13. COX JB, Nukui M, Murphy EA
    Protein-S-nitrosylation of human cytomegalovirus pp65 reduces its ability to undermine cGAS.
    J Virol. 2025 Apr 17:e0048125. doi: 10.1128/jvi.00481.
    PubMed         Abstract available


    JAMA

  14. MOIN EE, Seewald NJ, Halpern SD
    Use of Life Support and Outcomes Among Patients Admitted to Intensive Care Units.
    JAMA. 2025 Apr 14:e252163. doi: 10.1001/jama.2025.2163.
    PubMed         Abstract available


    Lancet

  15. AMOUZOU A, Barros AJD, Requejo J, Faye C, et al
    The 2025 report of the Lancet Countdown to 2030 for women's, children's, and adolescents' health: tracking progress on health and nutrition.
    Lancet. 2025 Apr 9:S0140-6736(25)00151-5. doi: 10.1016/S0140-6736(25)00151.
    PubMed        


    Nature

  16. BIEVER C
    First global pandemic treaty agreed - without the US.
    Nature. 2025 Apr 16. doi: 10.1038/d41586-025-00839.
    PubMed        

  17. KRAWCZYK PS, Mazur M, Orzel W, Gewartowska O, et al
    Re-adenylation by TENT5A enhances efficacy of SARS-CoV-2 mRNA vaccines.
    Nature. 2025 Apr 16. doi: 10.1038/s41586-025-08842.
    PubMed         Abstract available

  18. DE KEERSMAECKER J, Van Bavel JJ
    Scientists must regain trust.
    Nature. 2025;640:602.
    PubMed        


    Travel Med Infect Dis

  19. FERRIS LJ, Kang J, Rathbone JA, Cruwys T, et al
    Vaccine uptake and adherence to non-pharmaceutical interventions at a youth mass gathering event: A longitudinal field cohort study.
    Travel Med Infect Dis. 2025 Apr 13:102853. doi: 10.1016/j.tmaid.2025.102853.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »